L3Harris Technologies LHX

Reference table

1. What it is

L3Harris Technologies (NYSE: LHX) is a Melbourne, Florida–based prime defense contractor, the product of the 2019 merger of Harris Corporation (founded 1895) and L3 Technologies. It sells mission systems, tactical communications, electronic warfare, ISR (intelligence/surveillance/reconnaissance), space payloads, night vision, and — since the 2023 Aerojet Rocketdyne acquisition — missile and space propulsion. It employs ~47,000 people. Fiscal year ends the Friday nearest December 31.

Revenue mix. Note a wrinkle: the FMP product segmentation still reports the legacy four-segment structure (Integrated Mission Systems, Space & Airborne Systems, Communication Systems, Aerojet Rocketdyne), while as of 2026 management has re-organized into three reportable segments — Space & Mission Systems, Communication & Spectrum Dominance, and Missile Solutions (per the Q1'26 earnings release). We show both so the numbers reconcile:

• By legacy segment (FY2025, FMP): Space & Airborne Systems $6.95B · Integrated Mission Systems $6.63B · Communication Systems $5.67B · Aerojet Rocketdyne $2.85B. Total ~$21.87B.
• By new segment (Q1'26, from the earnings release): Space & Mission Systems $2.99B (+24% YoY) · Communication & Spectrum Dominance $1.86B (+3%) · Missile Solutions $0.99B (+18%). The Space/ISR and Missile lines are carrying the growth.
• By geography: predominantly US government. FMP's geo breakout is sparse (it tags ~$4.8B of FY25 revenue to segment-level international and a ~$1.7B "Non-US" line in prior years), but the practical read is a US-defense-concentrated revenue base with a growing international mix that management is leaning into.

The strategic frame management uses is the "Trusted Disruptor" strategy and a "2028 Financial Framework" — margin expansion, cost-out ("LHX NeXt"), and monetizing legacy assets. There is also a planned public offering / partial spin of Missile Solutions flagged in the filing.

2. The expert thesis (no expert coverage — stated plainly)

There is zero expert coverage of LHX in the Synthos knowledge base. total_claims is 0; there are no net-bullish or cautionary voices, and no claim_id values exist to cite. Per Synthos house standard, we do not fabricate conviction: this verdict is entirely fundamentals- and quant-driven, built from FMP financials, analyst estimates, management's own SEC-filed guidance (half-weighted, §9), and the technical block.

What that means for the reader: treat the conviction rating as Low by construction. The bull/base/bear scenarios in §3 are our own scenario model, not an aggregation of outside experts. Where the Street disagrees with us (it is more bullish), we show that as context in §6 — but we anchor to our own base case, not to the consensus target.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$290 (−4%), with the full $210–$345 span as the honest range. Our base sits below the Street's $347 consensus — we give less benefit of the doubt to the forward multiple and take the leverage/budget risk more seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). LHX is a steady defense compounder — decidedly not an exponential:

• Forward growth: revenue CAGR FY25→FY30E ~6.3% ($21.9B → $29.7B); EPS CAGR ~15.8% ($8.53 → $17.78) — the gap between the two is the whole story: growth is margin-and-buyback-driven, not volume-driven.
• Acceleration (the 2nd derivative): modestly positive but small. Revenue growth per consensus runs ~0.6% (FY26E, understated — see below) → ~7% (FY27E) → ~8% (FY28E), then eases to ~6%. This is a demand upcycle (Ukraine/Israel restocking, munitions acceleration, allied budgets rising toward 3–5% of GDP), not a technology inflection. Note: the FMP FY26E revenue figure (~$22B) looks stale — management guides FY26 revenue to $23–23.5B, so near-term growth is understated in the consensus table.
• Room to run: the TAM is real and rising (global defense budgets), but it is bounded by government appropriations — there is no consumer-adoption S-curve here. At $56B market cap in a duopoly/oligopoly of primes, LHX is neither tiny nor uncapped.
• Reinvestment runway: capex is light (~$0.4–0.6B/yr, ~2% of revenue); capital return (buybacks + a 1.6% dividend) is the primary use of FCF. That's shareholder-friendly but it's the profile of a mature compounder, not a reinvestment-driven exponential.

Exponential Potential: Low (3/10). Own LHX (if at all) for steady low-teens total return via EPS growth + capital return, not for a fast multibagger. A small, accelerating name would score far higher on this axis; LHX honestly does not.

5. Financials (real numbers — FMP annual/quarterly + Q1'26 earnings release)

• Revenue: FY25 $21.87B, +2.5% (FY24 $21.33B; FY23 $19.42B — the FY23→24 jump reflects the full-year Aerojet Rocketdyne addition). Q1'26 $5.74B, +12% reported / +15% organic — a clear reacceleration.
• Quarterly trajectory: Q1'25 $5.13B → Q2 $5.43B → Q3 $5.66B → Q4 $5.65B → Q1'26 $5.74B. Steady, with Q1'26 up 12% YoY.
• Margins: gross 25.3% TTM, segment operating margin 15.7% (Q1'26, up 10 bps), total operating margin 11.4% (up 120 bps YoY), net 7.7% TTM. Margins are expanding — the core of the earnings-growth story.
• Earnings: net income $1.61B FY25 (EPS $8.53 diluted), up from $1.50B FY24. Q1'26 EPS $2.72, +33% YoY — a strong start driven by operating leverage, lower interest expense and a lower tax rate.
• Cash flow: FY25 operating CF $3.11B, capex −$0.42B, FCF $2.68B (FCF yield ~4.6%). Management guides FY26 operating CF to ~$3.6B. Note Q1 is seasonally FCF-negative (−$187M) on working-capital timing.
• Balance sheet: total debt $11.25B, net debt $10.18B, net-debt/EBITDA ~2.8× — investment-grade (rated "B" on FMP's letter scale) but the most notable risk on the sheet. Deleveraging from ~3.4× post-Aerojet is underway (net debt down from $13.4B in FY23). Goodwill + intangibles are $26.5B (64% of assets) — tangible book value is negative, a legacy of acquisition-heavy history.

6. Valuation — priced in or room?

LHX is not cheap, not egregious. Trailing 33× EPS, EV/EBITDA 17.4×, EV/S 3.0×, P/FCF ~22×. The forward multiple compresses as margins expand: 28× FY26E → 26× FY27E → 22× FY28E → 17× FY30E on consensus EPS. The PEG-style read: ~28× forward against ~16% forward EPS growth is roughly a 1.8× forward PEG — full, but not absurd for a low-beta defense compounder with a record backlog.

The bull's case is that (a) the backlog (1.4× book-to-bill) de-risks the revenue, (b) the margin framework and LHX NeXt cost-out keep EPS compounding faster than revenue, and (c) a Missile Solutions spin surfaces value. The bear's case is that (a) 2.8× leverage magnifies any budget-driven revenue miss, (b) ROIC is only ~5% (below cost of capital on a goodwill-heavy base), and (c) at 28× forward there's simply little margin of safety.

Street targets (context): consensus $347 (high $364, low $323; 24 Buy / 6 Hold / 2 Sell). Our base-case FV of ~$290 is below the Street — we discount the forward multiple and weight the leverage/budget risk more heavily. When our number is below consensus, we say so: this is why the verdict is Watch, not Buy.

7. Technicals (from the tech block)

• Trend: down. $302 sits below the 50-DMA ($306.7) and the 200-DMA ($316.4), with the 50 below the 200 — a mild downtrend posture. MACD −5.1 (negative).
• Location: −20% off the 52-week high ($378.5), +19% off the 52-week low ($253.6). The stock has round-tripped a meaningful drawdown (max −20% from peak) and is in the lower-middle of its range.
• Momentum: RSI(14) 43 — neutral-to-weak, neither oversold nor overbought. No stretched-entry signal either way.
• Relative strength: LHX +19.8% 12-mo vs SPY +20.6% — an in-line-to-slight-laggard, and −14.6% 3-mo vs SPY +13.7% — recent underperformance. It has lagged QQQ badly (QQQ +30% 12-mo).
• Read: technicals do not confirm a buy here — the stock is below both moving averages and has underperformed the market over the last quarter. A base above the 200-DMA (~$316) or a pullback toward the low-$250s would be a cleaner technical setup. This weakness reinforces the fundamental Watch.

8. Moat & competitive position

L3Harris's moat is the standard prime-contractor moat: (1) entrenched, long-cycle program positions with the US DoD and allies (switching costs are enormous mid-program); (2) classified/cleared capabilities and facilities that create high barriers to entry (ISR, EW, secure comms, space payloads); (3) scale and vertical integration — the Aerojet Rocketdyne acquisition brought captive missile/space propulsion. The record $40.7B backlog is the tangible expression of that moat — multi-year revenue visibility.

The limits: it is the #6 US prime (behind LMT, RTX, GD, NOC, BA), a price-taker on most cost-plus and fixed-price government contracts, subject to budget cycles and unilateral government contract action, with only ~5% ROIC on a goodwill-heavy base.

Peer set (from FMP, market cap): Northrop Grumman $78B (the closest pure-play defense comp), United Rentals $69B, PACCAR $63B, Carrier $58B, AMETEK $54B, HEICO $50B, Axon $48B, Ferguson $45B, Roper $37B. Note the FMP peer list is a mixed industrials bag; the truest defense comps for LHX are NOC, plus (not listed) LMT, RTX, GD. Among these, LHX trades at a mid-range multiple with lower ROIC than the higher-quality industrials (HEICO, Roper, AMETEK) but a genuine defense tailwind those lack.

9. Management, capital allocation & guidance

• Capital allocation: balanced — deleveraging (net debt down $3.2B from the FY23 Aerojet peak), buybacks (~$1.15B FY25), a growing dividend (~1.6% yield, ~53% payout), and light capex. Appropriate for a mature prime; the buyback is the swing lever for EPS growth.
• Insider activity: the sampled window shows only routine director equity awards (grants at $0/$293) and no meaningful open-market discretionary selling — neutral read, no alarm signal.
• Management's own guidance (the earnings-call track — half-weighted, they talk their book): The Q1'26 earnings release (SEC 8-K, filed 2026-04-30) is a real earnings release and reads as such. Management's self-interested but dated guidance:

- FY2026 revenue $23.0–23.5B and GAAP diluted EPS $11.40–11.60 (raised from a prior $11.30–11.50).

- Segment operating margin "low 16%" for the year; operating cash flow ~$3.6B, capex ~$600M (implying ~$3.0B FCF).

- Record backlog $40.7B, book-to-bill 1.4×, orders $7.8B in the quarter.

- Reaffirmed the 2028 Financial Framework and flagged a planned public offering of the Missile Solutions business.

- CEO Chris Kubasik framed it around the "Trusted Disruptor" strategy and "demand accelerating." Half-weight this — it's management's own book — but the guidance raise and the backlog are corroborated by the reported Q1 numbers.

10. Catalysts & what to watch

• Next earnings: 2026-07-23 (Q2'26; Street EPS $2.79, revenue ~$5.79B). Key lines: book-to-bill / backlog (does the 1.4× hold?) and segment operating margin (the framework's credibility).
• Missile Solutions public offering / spin: timing and valuation — a potential value-unlock catalyst management has explicitly flagged.
• US defense budget / appropriations: FY27 budget posture, munitions-acceleration funding, and any continuing-resolution risk — the single biggest swing factor for the revenue line.
• Deleveraging: continued progress toward the lower end of the leverage range would de-risk the balance sheet and support a re-rating.
• International orders: allied budget increases (NATO toward 3–5% of GDP) converting to LHX bookings.

Thesis tripwires (what would change the call): a book-to-bill falling below 1.0× for two quarters; a budget-driven revenue guide-down; leverage rising back toward 3.5×+; or the margin framework visibly slipping. A pullback into the low-$250s with backlog intact would flip this toward Buy — Tactical.

11. Key risks

• US-budget dependence (structural): the overwhelming majority of revenue is US-government and allied defense — exposed to appropriations, continuing resolutions, program cancellations and unilateral government contract action.
• Leverage (2.8× net-debt/EBITDA): above the peer-quality set; magnifies any earnings miss and constrains flexibility if rates or a downturn bite.
• Valuation / de-rating: 28× forward on ~6% revenue growth leaves little margin for a disappointment.
• Low returns on capital: ~5% ROIC on a goodwill-heavy balance sheet (64% intangibles, negative tangible book) — the acquisition-built model earns modest returns.
• Execution / EAC risk: fixed-price defense programs carry estimate-at-completion (EAC) charge risk; margin framework depends on program performance holding.
• No expert corroboration: with zero KB coverage, this call rests solely on the numbers — lower conviction by construction.

12. Verdict, position sizing & monitoring

Watch. L3Harris is a genuinely well-run mid-cap defense prime in a real demand upcycle — record $40.7B backlog, 1.4× book-to-bill, +33% Q1'26 EPS, expanding margins, and a management team that just raised full-year guidance. Those are all Buy-shaped facts. But the stock is priced for them: 28× forward, ~6% revenue growth, 2.8× leverage, ~5% ROIC, and a technical downtrend (below both moving averages, −20% off its high). Our base-case fair value (~$290) sits below both the current price and the Street's $347 — so the honest verdict is Watch, not Buy. We'd want a lower entry (low-$250s) or a clearer growth/deleveraging inflection to upgrade.

• Sizing: if held, satellite/defensive, ~1–3% — a steady total-return holder for a defense sleeve, not a high-conviction core position. Given the technical weakness, patience on entry is warranted.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-23). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $302.07.
• Single biggest risk: US defense-budget dependence colliding with 2.8× leverage — a budget stall would hit a levered balance sheet harder than a cash-rich peer's.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — there is no expert coverage of LHX in the Synthos knowledge base. This verdict is fundamentals- and quant-driven; no claim_id values are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we state the absence of coverage plainly rather than manufacturing a thesis.
• Data as-of: fundamentals 2026-04-03 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K filed 2026-04-30. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates/guidance.
• Segment note: FMP reports the legacy four-segment structure; management reorganized to three segments (Space & Mission Systems, Communication & Spectrum Dominance, Missile Solutions) in 2026 — both shown in §1 for reconciliation. FMP's FY26E revenue (~$22B) appears stale vs management's $23–23.5B guide.
• Management caveat: the FY26 guidance in §9 is management's own book, half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").